Bayer: Xarelto shows heart benefit in large study.
(CercleFinance.com) - Bayer said on Sunday that Xarelto significantly lowered the combined risk of stroke, cardiovascular death and heart attack in a phase III study.
When added to aspirin, the oral anticoagulant reduced this risk by 24% in patients with chronic coronary artery disease or peripheral artery disease, the German drugmaker said.
The drug, when combined with aspirin, also showed a 42% relative risk reduction in stroke and 22% in cardiovascular death compared with just aspirin taken once daily.
This data, from 27,395 patients, was presented at the ESC Congress 2017 at the week-end.
"Xarelto achieved to demonstrate its strong therapeutic activity (...), offering to Bayer the opportunity to access a new market," analysts at Bryan Garnier reacted on Monday, reiterating their "neutral" rating on the shares, with a fair value of 108 euros.
However, the shares were not moving much on this news, currently down 0.2 percent at 108.7 euros in Frankfurt.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
When added to aspirin, the oral anticoagulant reduced this risk by 24% in patients with chronic coronary artery disease or peripheral artery disease, the German drugmaker said.
The drug, when combined with aspirin, also showed a 42% relative risk reduction in stroke and 22% in cardiovascular death compared with just aspirin taken once daily.
This data, from 27,395 patients, was presented at the ESC Congress 2017 at the week-end.
"Xarelto achieved to demonstrate its strong therapeutic activity (...), offering to Bayer the opportunity to access a new market," analysts at Bryan Garnier reacted on Monday, reiterating their "neutral" rating on the shares, with a fair value of 108 euros.
However, the shares were not moving much on this news, currently down 0.2 percent at 108.7 euros in Frankfurt.
Copyright (c) 2017 CercleFinance.com. All rights reserved.